OQRO

Cingulate

CING · NASDAQ · Health Care · Pharmaceutical Preparations

Pharmaceutical Preparations company based in Kansas City, Ks.

Example public filing

SEC Form 4

Director bought ~$490K

Thomas Jeffrey Hargroves, Director at Cingulate, bought ~$490K of Cingulate shares.

~$490K
Approx. value · 97K sh @ $5.04
97K
Holds after · shares reported
Traded
Feb 13, 2026
Filed
Jun 8, 2026

Data as of Oct 11, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.

On file for CING, last 12 months

40
Insider filings
0
Congress trades
0
Fund positions
0
Federal contracts

Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.

Insider buying and selling since 2021

Insiders of Cingulate reported 42 open-market purchases and 2 sales since 2021; purchases in 4 different years, most recently 2026.

YearBoughtSold
2026
5×
—
2024—
1×
2023
4×
—
2022
29×
1×
2021
4×
—

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.

See the full picture with OQRO Pro.

40 records for Cingulate in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.

Latest disclosures

SourceWhoAction
Unlock full access — $9.99/month

Secure payment by Stripe. Renews every month until you cancel; cancel anytime from your account. No free trial.

Continue exploring the free preview

Public previews are free. Full research requires Pro. No free trial.

What this page holds

  • Insider trades and planned sales
  • Politician trades (House and Senate)
  • Fund holdings from 13F filings
  • Federal contracts, lobbying and short selling
  • Full history and context, with a link to every filing

What OQRO is

OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.

Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.

Questions about Cingulate insider trading

Have Cingulate insiders bought shares recently?

No open-market purchase by an insider of Cingulate was filed in the last 90 days. The latest on record was on Jun 8, 2026.

How often do Cingulate insiders buy and sell shares?

Since 2021, Cingulate insiders reported 42 open-market purchases and 2 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2026.

Do members of Congress trade CING?

No trade in Cingulate (CING) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

What this filing is, free to read